ICU SEASTAR MEDICAL HOLDING CORPORATION

SeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference

SeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference

DENVER, Sept. 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024 at 9:00 a.m. Eastern time. A webcast of the fireside chat will be available on the section of the Company’s website.

Management is available for in-person and virtual one-on-one meetings throughout the conference being held September 9-11. Institutional investors and industry professionals can to attend the conference virtually or in-person at the Lotte New York Palace Hotel.

About SeaStar Medical

SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on or .

Contact:

LHA Investor Relations

Jody Cain

(310) 691-7100

# # #



EN
05/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEASTAR MEDICAL HOLDING CORPORATION

 PRESS RELEASE

SeaStar Medical Announces Completion of FDA Enrollment Requirement for...

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for ch...

 PRESS RELEASE

SeaStar Medical Announces Publication in Pediatric Nephrology of Posit...

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI) Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today the publication of early post-approval clinical experience from the use of the  in the prestigious, p...

 PRESS RELEASE

SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging ...

SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, February 5th at 11:30 am Eastern Time. Interested investors and guests of ...

 PRESS RELEASE

SeaStar Medical Announces 2026 Milestones

SeaStar Medical Announces 2026 Milestones Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical’s first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion market – through completion of enrollment of the NEUTRALIZE-AKI pivotal trial and initiation of the PMA process Progress the clinical development of the SCD therapy in patients with severe heart failure Leverage rapid pathways to commercialization of the SCD therapy through additional FDA Humanitarian Use and Breakthrough Device Desi...

 PRESS RELEASE

SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor ...

SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Biotech Showcase 2026 Investor Conference at the Hilton Union Square, San Francisco, CA, on January 13, 2026, at 3:00 p.m. Pacific Standard Time. The live presentation wi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch